Delivery Order SPE2DB25D3306-SPE2DB25FUBTJ
- Not listed
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $1,991.52 to AmerisourceBergen Drug Corp for Deferasirox 500 mg tablets for suspension (30-count units) on September 24, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award, and is scheduled for completion by September 25, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a delivery order valued at $47,526.27 to AmerisourceBergen Drug Corp for the supply of Deferasirox 360 mg tablets (30-count units). This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by September 5, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Deferasirox 360 mg tablets (30-count packages) under a firm fixed-price contract with a ceiling value of $43,387.99. The order was competitively awarded without set-aside designation and is scheduled for completion by August 8, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,583.96, is a Delivery Order for the supply of 4,566,199 units of the drug Deferasirox 360 mg Tablet, packaged in 30s. The contract has an ultimate completion date of October 25, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Deferasirox 360 mg tablets in a quantity of 30 units. This is a firm fixed price delivery order valued at $35,982.29, with a completion date of September 25, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a child contract under a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Deferasirox 500 mg Tablets for Suspension. The contract has a ceiling value of $5,629.92 and an ultimate completion date of September 13, 2024. This is a Firm Fixed Price contract for the delivery of this pharmaceutical product. The award is not associated with any set-aside designation. As one of the largest pharmaceutical distributors in the United States, AmerisourceBergen...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide DEFERASIROX 360 MG TABLET 30S. The firm fixed price contract has a potential value of $13,105.98 and a performance completion date of December 29, 2023. No set-aside designation was used. Amerisourcebergen Drug Corp is a prime contractor that has received numerous federal contract awards from DLA to supply pharmaceuticals, medical...
- This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation's Corporate Office division. The contract is for the supply of 4565192602 - Deferasirox 360 mg Granule Packets, 30s. This order is part of a larger Indefinite Delivery Contract (IDC) between DLA Troop Support Medical and AmerisourceBergen valued at up to $999,999,999 through December 2025, which provides a comprehensive range of pharmaceutical and...
- AmerisourceBergen Drug Corp received a $37,524.35 delivery order from the Defense Logistics Agency (DLA) on July 17, 2025, for the supply of Jadenu 360 mg tablets (30-count units). This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Jadenu is an iron chelation therapy medication used to treat chronic iron overload, a condition common...
- This federal contract award is for the delivery of 50 tablets of the pharmaceutical drug deferiprone, 1,000 mg per tablet, with a 3-times-per-day dosage requirement. The contract, valued at $13,040.76, was awarded to Amerisourcebergen Drug Corp, Corporate Office Division, by the Defense Logistics Agency (DLA) Troop Support Medical. The award is a delivery order under the DLA's Indefinite Delivery Contract (IDC) valued up to $999,999,999 through December 2025, which provides a comprehensive range...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUBTJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 360 mg Deferasirox tablets (30-count units) on May 16, 2025, with a ceiling value of $5,673.37 and an ultimate completion date of May 19, 2025. This is a firm fixed-price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The award represents a competitive, non-set-aside contract, reflecting AmerisourceBergen's established capability as a major pharmaceutical distributor serving federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, functions as a critical vendor for the Defense Logistics Agency's Medical Supply Chain, supplying a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. Deferasirox is an iron chelation therapy medication used to treat chronic iron overload conditions. Through its prime IDC vehicle with DLA, AmerisourceBergen maintains the flexibility to fulfill diverse pharmaceutical requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, with the company positioned as a potential contractor for DLA's forthcoming Pharmaceutical Prime Vendor Global Program Generation V contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 5/16/25 |